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Abstract: Thrombin is a plasma serine protease that plays a key role in coagulation and hemostasis but also in throm-
boembolic diseases. Direct thrombin inhibitors could be beneficial for future anticoagulant therapy in the prophylaxis of 
venous and arterial thrombosis as well as myocardial infarction. To design the efficient thrombin inhibitors we have syn-
thesized and studied peptide-based inhibitors resistant to enzymatic degradation. Compounds with general formula X-D-
Arg-D-Phe-OMe, where X = residue of 3-[6-ethyl-7-hydroxy-3-(4-methyl-thiazol-2-yl)-4-oxo-4H-chromen-2-yl]-
propionic acid (chromone) and lauric acid were synthesized by classic methods of peptides synthesis in solution. The 
comparative inhibitory analysis of prepared compounds in relation to thrombin was conducted. The analysis of the inhibi-
tion effect of the peptide with retro-D-sequence modified by residues of natural organic compounds (chromone or fatty 
acid moiety) has demonstrated that modification with the fatty acid residue appeared to be the most successful one. Intro-
duction of lauric acid residue (Ki = 1,76 μM) maximally increased the inhibition effect. These findings establish an impor-
tant role of fatty moiety in structure of inhibitors in preferential binding and inhibition of thrombin active side. 
Keywords: Thrombin, inhibitors, peptides, chromone, lauric acid. 
INTRODUCTION 
  Thromboses and thromboembolic diseases are the most 
widespread in developed countries. In present medical prac-
tice the natural thrombin inhibitor – heparin and its low-
molecular fragments are widely used, which act by forma-
tion of the triple complex with thrombin and antithrombin 
III– as anticoagulants of direct action (Mousa SA. In Meth-
ods Mol. Med. 2003) [1] (Smith Thromb. Res. 1981) [2]. 
Warfarin is a coumarin derivate which is used as the antico-
agulant of indirect action, an antagonist of synthesis of vita-
min K dependent enzymes, which include the precursor of 
thrombin – prothrombin (O’Reilly In Hemost. Thromb. 
1987) [3]. Several pharmaceutical companies have therefore 
very intensely pursued the search for low molecular weight 
active site thrombin inhibitors over the past years. However, 
development of direct thrombin inhibitors has brought re-
searchers more “headache” than success. The most recent 
setback came when AstraZeneca withdrew Ximelagatran, the 
first orally bioavailable direct thrombin inhibitor that had 
received regulatory approval, after reports of a significant 
risk of potentially lethal hepatic toxicity in a fraction of pa-
tients (Testa Int. J. Cardiol. 2007) [4].  
  Thrombin (EC 3.4.21.5), the key enzyme of the hemosta-
sis system, is the therapeutic target to create anticoagulants 
of direct action – effective pro-drugs for treatment of throm-
boembolic diseases (Sanderson Current Medical Chemistry 
1998) [5] (Bauer Hematology  2006) [6]. Structures of the   
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active site of thrombin as well as numerous functions are 
currently well studied (Fenton Blood Coagu. Fibrino. 1991) 
[7] (Bode Journal of Thrombosis and Haemostasis 2005) [8] 
(Stubbs Thromb. Res. 1993) [9] (Huntington J.  Thromb. 
Haemos. 2005) [10]. X-ray structural analysis data of com-
plexes of thrombin with inhibitors enabled to design new 
inhibitors of the enzyme with high efficiency (Bode A Pro-
tein Science 1992) [11].  
  The special attention is devoted to selectivity of inhibi-
tors, which can be effectively provided by substances of the 
peptide nature. Unfortunately, recently this class of com-
pounds has not been causing an interest because peptides are 
characterized by extraordinarily low bioaccumulation due to 
non-specific degradation by proteases that reduce an inhibi-
tor delivery probability to chosen target enzyme. To prolong 
the lifetime of low-molecular peptide inhibitors of thrombin, 
that is to make them invulnerable to non-specific hydrolysis 
by proteases, we have applied to design them topochemical 
approach introduced by Shemyakin, Ovchinnikov and 
Ivanov (Shemyakin Angew. Chem. 1969) [12]. The key 
point of this approach consists in synthesis of retro-D-
analogues of natural biologically active peptides. Peptides 
with the retro-D-sequence are resistant to enzymatic degra-
dation of the reversed amide bond and preserve ability to 
binding with the proper active sites of enzyme.  
  However, this approach has been productive only for 
cyclopeptide compounds, but linear retro-D-analogues pre-
serving a resistance to enzymatic hydrolysis had low bio-
logic activity. We decided to modify this approach by inser-
tion of natural compound residue into the peptide motif in 
order to intensify the biologic effect of compounds. 144    The Open Biochemistry Journal, 2008, Volume 2  Poyarkov et al. 
  Many thrombin inhibitors share the D-Phe-Pro-Arg motif 
mimicking the binding region of the natural substrate fi-
brinogen (Bajusz J. Med. Chem. 1990) [13] (Brady Bioorg. 
& Med. Chem. 1995) [14] (Bajusz Bioorg. Med. Chem. 
1995) [15]. A number of known inhibitors such as inogatran 
and melagatran (active form of ximelagatran) have been de-
veloped based on this motif (Preville Bioorg. Med. Chem. 
Lett. 1997) [16] (Gustafsson Thromb. Res. 2001) [17]. Pep-
tidomimetic thrombin inhibitors with different modifications 
by isosteric amino acids of this thrombin inhibiting tripeptide 
chain were also synthesised (Nöteberg. Med. Chem. 2000) 
[18] (Throstensson J. Med. Chem. 2003) [19].  
  Notwithstanding, we have demonstrated that dipeptide 
Tos-Phe-Arg-OCH3 is both the substrate and inhibitor of 
thrombin and has an (IC50 = 20 μM) appropriate characteris-
tics to be transformed into the retro-D-sequence with effi-
cient binding in the active site of thrombin (Poyarkova 
Ukrainskii Biokhimicheskii Zhurnal 1986) [20]. Retro-D- 
sequence of this dipeptide D-Arg-D-Phe was successfully 
used as ligand of the affinity sorbent for highly purified 
thrombin preparation with the activity of 6000 NIH /mg 
(Haga SU Patent 1527261, 1989) [21]. Therefore we used D-
Arg-D-Phe motif to create a new thrombin inhibitors resis-
tant to enzyme degradation and carried forward biological 
active blocks which are useful for others steps of cascade co-
agulation. 
  There are no data about synthesis and inhibitory effect of 
retro-D-peptides, modified by natural aromatic and fatty acid 
moieties. In this study we synthesized, investigated anti-
thrombotic activity and compared inhibitory activity of new 
thrombin inhibitors high-resistant to enzymatic digestion. 
This study provides new insights into the role and effect of 
fatty acid tail on the interaction behaviors with the secondary 
binding site of thrombin and is important for future devel-
opment of new anticoagulants, non toxic and resistant to 
enzymatic degradation. 
MATERIALS AND METHODS 
  Amino acids, fatty acids and solvents were pursued from 
"Merck" (Germany), condensing agents - from “Sigma” 
(Germany). The reaction control and purity of the products 
were monitored by TLC on plates with Silica gel 60 F254 
(“Merck” Germany) (n-butanol/acetic acid/water, 4:1:1, v/v 
(A); benzene/ethyl acetate, 5:4, v/v (B); chloro-
form/methanol, 8:2, v/v (C). After chromatography the plates 
were developed with ninhydrin, iodine, Sakaguchi reagent or 
ammonium molybdate. rpHPLC separation was conducted 
on Waters chromatography system equipped with two 510 
Waters High pressure pumps, 996 Waters PDA detector with 
base wavelength 214 nm.  
  The molecular masses were analyzed by LDI mass spec-
trometry on Bruker AUTOFLEX II LRF20 spectrometer. 
  1H NMR spectra were registered on a Varian VXC-400 
(Germany) (400 MHz) in DMSO- d6 (99.9%) relative to 
residual solvent protons. 
Methods of Synthesis 
  Methyl ester of carbobenzoxy-D-arginyl-D-phenylala-
nine (1) was synthesized as described in the work (Haga SU 
Patent 1527261, 1989) [21]. 
  A mixture of Z-D-Arg (4,51g, 14,6 mmol) and D-Phe-
OMe (3,2g, 14,8 mmol) was dissolved in 30 ml of absolute 
pyridine and was stirred for 30 min, then was cooled to 0°C. 
DCC (3,06 g, 14,8 mmol) was added to the cold solution. 
The reaction mixture was stirred for 6 hours at 0°C and kept 
for 24 hours at room temperature. The precipitate obtained 
was filtered, and the solvent was evaporated under vacuum 
at 40°C. The residue was dissolved in butanol-2 and washed 
with the saturated solution of NaCl and 1N HCl. Butanol-2 
was evaporated, and the residue was crystallized from the 
mixture of methanol – ethyl acetate. The yield 1 was 5, 84 g 
(92%); mp 80-98°C; Rf = 0,65 in the system (A). Data of the 
element analysis: Found %:  = 57, 21; 	 = 6,17; N = 13,64. 
24	31N5
5.HCl.H2O; calcd %:  = 56,97; 	 = 6,18; N = 
13,84. 
  Methyl ester of N - lauroyl-D-arginyl-D-phenylalanine 
(3) was similarly synthesized from 0,5 g (1,27 mmol) of 
monohydrochloride of lauroyl-D-arginine [31], 0,27g (1,27 
mmol) of D- phenylalanine methyl ester and DCC 0,27 g 
(1,30 mmol). The product obtained was crystallized from 
ethyl acetate, 0,5g (70%); mp 92-93˚; Rf = 0,43 in the sys-
tem (B). Data of the element analysis: Found %:  =61.01; 
	 = 9.01; N =12,28. 28	47N5
4   HCl ; calcd %:  
=60,69; 	 = 8,73; N =12,64. HPMS m/z 518,083 ( + 	)+ 
calcd for C28H47N5O4 517, 70 
  N-oxysuccinimide ester 3-[6-ethyl-7-hydroxy-3-(4-
methyl-thiazol-2-yl)-4-oxo-4H-chromen-2-yl]- propanoic 
acid 0,4 g (1 mmol) of 3-[6-ethyl-7-hydroxy-3-(4-methyl-
thiazol-2-yl)-4-oxo-4H-chromen-2-yl]-propanoic acid syn-
thesized as described in the work (Poyarkov Russian J. 
Bioorg. Chem. 2005) [22] were dissolved in 20 ml of dis-
tilled DMF, and at cooling to 4°C N-hydroxysuccinimide 
(0,12 g, 1,01 mmol) and DCC (0,21g, 1,01 mmol) were 
added. The mixture was stirred for 12 hours at 4°C. After 
reaction completion (control – TLC) the precipitate DCU 
was filtered, DMF was evaporated in vacuum at 40°C. The 
residue was crystallized from iso-propanol; 0,4g (80%); mp 
110°; Rf=0.6, (B) benzene ethyl-acetate (5:4). 
  Methyl ester of D-arginyl-D-phenylalanine (1a) 1 ml of 
5,6 N HCl and 1 g of catalyst Pd/C was added to solution of 
5,84 g (1) in 30 ml of methanol, and hydrogen was passed 
through the suspension for 10 hours at the ambient tempera-
ture and stirring. The catalyst was filtered, a solvent was 
evaporated, and the precipitate was crystallized from abso-
lute ether. Yield 4,37 g (93%); mp 148-152° C; Rf = 0,15 
(A) (4:1:1). 
  Methyl ester 3-[6-ethyl-7-hydroxy-3-(4-methyl-thiazol-2-
yl)-4-oxo-4H-chromen-2-yl]-propionyl-D- arginyl-D-
phenylalanine). (2) To solution of 0,3 g (0,735 mmol) of D-
arginyl-D-phenylalanine methyl ester hydrochloride in 20 ml 
of DMF 0,074 ml of N-methylmorpholine were added and 
the solution was stirred for 20 min. at room temperature, the 
precipitate of N-methylmorpholine hydrochloride was fil-
tered. N-oxysuccinimide ester of 3-[6-ethyl-7-hydroxy-3-(4-
methyl-thiazol-2-yl)-4-oxo-4H-chromen-2-yl]-propionic acid 
(0,3350 g, 0,735 mmol) was added to the filtrate. The reac-
tion mixture was stirred at ambient temperature for 48 hours, 
then the solvent was evaporated and the residue was crystal-
lized from ether. The product was purified by rpHPLC on 
the preparatory “Cromasil C18” column (10x250 mm) using 
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CH3CN and 0,1% of TFA) and phase B (with 80% CH3CN), 
respectively. The separation was conducted in conditions of 
linear gradient elution. The retention time of the target frac-
tion was 27,7 min. Solvent of the target faction was evapo-
rated, and the residue was crystallized from ether. Yield 0,2 
g (36%); mp 160ºC; Rf = 0,33 system (A) (4:1:1). 1H NMR 
(400 MHz, DMSO-d6) : 8,34-8,33 (1 H, d, J 4); 8,08-8,06 (1 
H, d, J 8); 7,8 (1 H, s,); 7,77 (1H, s,); 7,3 (5 H , m.); 7,19 (1 
H, s,); 6,95 (1 H, s,); 4,49 (1 H m, J 6); 4,36 (1 H, m, J 8,); 
3,61 (1 H, s,); 3,60 (5 H, m.); 3,55 (3 H, s.); 2,95 - 2,97 (2H, 
m.); 2,62 - 2,7 (2 H, m); 2,45 (3 H , s); 1,3 - 1,7 (4 H, m); 
1,24 (3 H, t. J 8,9). 
Thrombin Assays 
Inhibition of the Thrombin Coagulating Activity (IC50 De-
termination) 
  Preparation of fibrinogen solution as well as buffer solu-
tions for determination of coagulant activity of thrombin 
were carried out in accordance with the method (Baughman 
In Methods Enzymol. 1970) [23]. The starting solution of 
human thrombin isolated using the Fenton method (activity 
3000 NIH E/mg) was prepared so that the time of coagulat-
ing of 0,1 % solution of fibrinogen (Serva, 90% of coagu-
lated protein) made up 15-20 sec. under standard conditions 
(Fenton J. Biol. Chem. 1977) [24]. The study of the investi-
gated compounds on coagulant activity of thrombin was 
conducted at the following conditions. 0,04 M Tris-HCl 
buffer (pH 7,3) containing an inhibitor, 0,15 M NaCl and 
0,66% PEG 6000 (Serva) was added to 0,2% solution of fi-
brinogen (0,5ml) in the same buffer. The reaction mixture 
was thermo stated for 5 min. at 29°C, then treated with the 
starting thrombin solution (20 μl), and the time needed for 
clot formation was measured. The time of fibrinogen coagu-
lating was determined three times for 5-6 various concentra-
tions of peptide. The value of C50 was calculated from the 
curve (-0)/ 0 depend of [I], where 0 is the time of fi-
brinogen coagulating at absence of inhibitor;  is time of 
fibrinogen coagulating at presence of the explored com-
pound; [I] – concentration of inhibitor. 
Chromogenic Assays 
Inhibition of the Thrombin Amidolytic Activity 
  The inhibition constant (Ki) for dissociation of the en-
zyme-inhibitor complex was determined by a study the im-
pact of the inhibitor concentration on initial rate of p-
nitroaniline elimination from the chromogenic substrate of 
Tos-Gly-Pro-Arg-pNA (Chromozym TH). Change of rate of 
the enzymatic reaction was determined based on growth of 
p-nitroaniline absorption at the wavelength of 405 nm using 
a microtiter plate reader (Vmax Microplate Reader. Molecu-
lar Devices. USA) at the ambient temperature in the medum 
of 0,05M Tris/HC1 buffer of pH 8,0 containing 0,15 M NaCl 
and 0,66% PEG 6000. Compound 2 was studied in the same 
buffer containing 3% DMSO in final concentration. 
  Assays were performed according to the following gen-
eral procedure. The solution of human thrombin (1.67 nM) 
was added to the solution containing an inhibitor (varying 
concentrations, from 2 to 200 μ), incubated for 5 min. and 
the reaction was initiated by adding the substrate (250 μ), 
increase of absorption was registered every minute during 3 
min.  
  The data obtained were calculated in the Dixon system of 
co-ordinates (1/V÷ [I]) using EXCEL software. IC50 was 
defined from the linear dependence equation 
=	+b, as x =-
(b/a), where y=1/V, and x= [I] inhibitor concentration. The 
Ki value was calculated from the IC50 value using the equa-
tion, Ki = IC50/(1+[S]/Km) assuming a competitive enzyme 
inhibition. 
  The Km (26,3±0,18) μ value for (Chromozym TH) was 
defined at the same conditions at various concentrations of 
the substrate and calculated in double reverse co-ordinates of 
Lineweaver – Berk. The constants were determined based on 
three independent experiments. The experiment standard 
deviation did not exceed 10%. 
RESULTS 
  To construct structures of desired compounds, we se-
lected N-terminal substituents based on the following crite-
ria: 
  Compounds containing the chromone nucleus are univer-
sal pharmacophores (depending on substituents). 
(Mogilevich. In Chem. Bioregul. Proc. 1992) [25]. Moreo-
ver, dicoumarin (warfarin) is known to be the indirect anti-
coagulant, which suppresses synthesis of vitamin K depend-
ent proteins, including the precursor of thrombin – 
prothrombin (Smith Thromb. Res. 1981) [2]. Besides, re-
cently it was discovered that flavonoids inhibit the ami-
dolytic activity of human thrombin (Mozzicafreddo Bio-
chimie 2006) [26]. Therefore it is possible to assume that 
inhibitor degradation products, like coumarin analog sub-
stituent by itself, will make an impact on earlier stages of the 
blood coagulation cascade. 
  Fatty acids perform extraordinarily important functions 
in an organism, and their derivatives are supposed to possess 
the ability to penetrate through cells membranes that in-
creases a probability of inhibitor transportation to the chosen 
target (Leung J. Med. Chem. 2000) [27].  
 N--Lauroyl-L-arginine ethyl ester monochloride (LAE) 
is being developed as a novel preservative in selected foods 
and is being produced by Laboratorios Miret S.A. 
(LAMIRSA). It was shown that LAE possessed a very low 
toxicity and high antimicrobial activity (Ruckman Food 
Chem. Toxicol. 2004) [28], (Rodríguez J. Appl. Microbiol. 
2004) [29]. 
  The retro-D-sequence D-Arg-D-Phe was chosen as a pep-
tide motif because of affinity toward thrombin (Haga SU 
Patent 1527261, 1989) [21]. Involving into this sequence 
aromatic or aliphatic (in general hydrophobic) moieties in-
creases the affinity to enzyme by supplementary interactions 
with the hydrophobic region of thrombin, immediately adja-
cent to the active site. For this purpose we have developed 
appropriate synthetic methods for introduction of the aro-
matic or aliphatic moieties to D-peptides sequence. 
Chemistry 
  Modification of D-arginine on the -amino group with 
biologically active compounds was carried out using N-
oxysuccinimide esters of chromone as described in 
(Poyarkov Russian J. Bioorg. Chem. 2005) [22]. N-
Oxysuccinimide esters, along with their high reactivity, are 
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synthesis in aqueous dioxane. Use of N-oxysuccinimide es-
ters of acid derivatives of chromone and fatty acids enabled 
to obtain arginine derivatives in high yield and in some cases 
without extraction of intermediate N-oxysuccinimide esters 
of original acids. The derivatives with C-terminal free argin-
ine were easily purified by crystallization from water etha-
nol.  
  Carboxyl function of phenylalanine was protected by 
esterification with methyl alcohol. Condensation of protected 
amino acids was mainly conducted by the carbodiimide 
method in pyridine using protonated protection of the gua-
nidine function of arginine. To obtain the chromone deriva-
tive we used condensation of the corresponding N-
oxysuccinimide ester with hydrochloride of D-arginyl-D-
phenylalanine methyl ester in DMF, as indicated in Fig. (1). 
Purification of the compound Chrom-D-Arg-D-Phe-OMe 
was conducted by the rpHPLC method. Purity of the com-
pound obtained is proven by the NMR.  
Biological Activity 
  Biological activity of the synthesized compounds was 
studied by their ability to prolong the time of fibrinogen co-
agulation by thrombin and by inhibition of the thrombin's 
cleavage reaction of the chromogenic substrate of Tos-Gly-
Pro-Arg-pNA (Chromozym TH). (Table 1) 
  Measurements were conducted according to standard 
procedure which is carefully described in materials and 
methods.  
Table  1.  Inhibitory Activity of the Retro-D-Sequence of D-
Arg-D-Phe Peptides - Modified on the -Amino 
Group of Arginine 
 Compounds  IC50 μM Ki  μM 
1  Cbz-D-Arg-D-Phe-OMe 110  42±5 
2  Chrom-D-Arg-D-Phe-OMe* 56 
14,35 
±0,92 
3  Laur-D-Arg-D-Phe-OMe -//- 
1,76 
±0,09 
*Inhibitory effect was studied in the same buffer containing 3% DMSO in final con-
centration. 
 
  To estimate the anticoagulation action of synthesized 
compounds we explored a capability of these compounds to 
increase the time of formation of the fibrin clot at thrombin 
impact (Baughman In Methods Enzymol. 1970) [23]. As it 
follows from the IC50 values given in Table 1, compound 2 
possesses the maximal inhibition effect. The compound Cbz-
D-Arg-D-Phe-OMe (1), which has been already used for 
synthesis of the affined absorbent and as the started com-
pound for synthesis of the chromone derivative, also pos-
sesses anti-thrombin activity (IC50=110μM) which is twice 
lower than the corresponding activity of compound 2 that it 
indicates insufficient affinity of this compound to the active 
site of thrombin. Unfortunately, we could not determine IC50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Synthesis of the products. Reagents and conditions: a) D-Phe-OMe, DCCD /Pyridine; (b) H2/Pd, methanol; (c) HONSu, DCCD / 
DMFA; (d) 1a, N-methylmorpholine / DMFA. Influence of Aromatic and Aliphatic Moieties  The Open Biochemistry Journal, 2008, Volume 2    147 
for compound 3, due to its capability to precipitate the fi-
brinogen from its solution, this property needs additional 
study. Nevertheless it will be useful to decrease the fibrino-
gen concentration and to inhibit blood platelets aggregation. 
This process will be beneficial to prevent the risk of cardio-
vascular diseases. 
  Thrombin inhibition by the compounds was studied by 
their ability to reduce a rate of hydrolysis of Chromozym TH 
in the conditions of steady-state kinetics at [S] > 10 Km. As 
it follows from the data presented in Table 1, the maximal 
inhibition effect on amidolythic activity of thrombin is ob-
served for compound Laur-D-Arg-D-Phe-OMe 3 modified 
with the residue of lauric acid. The compound Chrom-D-
Arg-D-Phe-OMe 2 containing in its structure the chromone 
residue demonstrated a considerably worse inhibition effect. 
Definition of its activity was carried out in the same Tris 
HCl buffer containing 3% of DMSO due to its low solubility 
in water. The benzyloxycarbonyl derivative of dipeptide 1 is 
characterized by the minimum inhibition effect.  
DISCUSSION  
  The surprisingly low value of Ki of the compound 3 
modified with the lauric acid residue motivated us to conduct 
additional researches to get an understanding of the interac-
tion of such compound at the binding site of thrombin. N-
lauroyl-L-arginine ethyl ester (LAE) (partial L-analog of 
compound 3 is well known surfactant (Infante Fette Seifen 
Anstrichmittel. 1985) [30]). Nevertheless we studied inhibi-
tion effect of LAE earlier and showed that this compound 
selectively inhibits thrombin activity (Ki=2,0 M) almost in 
20 times more strongly than trypsin (	=19,0 ). At the 
same time LAE maintain capability to be hydrolyzed by 
thrombin at pH 8,5 (kcat = 3,6 -1) and trypsin (kcat = 56 -
1) (Poyarkov Ukrainskii Biokhimicheskii Zhurnal. 2007) 
[31]. 
  If the LAE interaction mechanism in the active center of 
thrombin is well-defined, the interactions of substituents of 
retro-D-chain are not absolutely clear. That is why the sup-
plemental experiments have been made. Studying of inhibi-
tion effect of Laur-DArg-DPhe-OMe on thrombin at differ-
ent substrate concentrations has shown the competitive char-
acter of inhibition Fig. (2) according to (Cornish-Bowden In 
Principles of Enzyme Kinetics 1976) [32]. 
 
 
 
 
 
 
 
 
 
Fig. (2). Plot for Ki estimation of Laur-DArg-D-Phe-OMe. [S]1, 
[S]2, and [S]3 are appropriate Chromozyme TH concentrations. 
 
  In this case, it is not quite appropriate to use the scheme 
by Schechter-Berger (Schechter Berger Biochem Biophys 
Res. Commun. 1967) [33] and it is more reasonable to con-
sider co-reaction with the active site of thrombin taking into 
account the structure of the secondary binding center of 
thrombin (Bode EMBO J. 1989) [34]. According to the data 
of X-ray analysis, the structure of the secondary binding site 
of thrombin is organized as so-called «hydrophobic cage» 
formed by the following residues of amino acid: Ile174, 
Trp215, Leu99, His57, Tyr60A and Trp60D. The special 
folding of thrombin  chain in the form of a stretched loop 
with Tyr60A and Trp60D located together with the Trp148 
forms a narrow and deep cleft of the active site. The indole 
rings of Trp60 D and Trp148 cover the cleft, thus hampering 
access to the active site of thrombin.  
  Taking into account that a length of synthesized peptides 
is limited by two amino acid residues and they have not rigid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Schematic representation of the binding mode of arga-
troban (MD 805) (a), and Laur-DArg-DPhe-OMe (b) to the active 
site of thrombin according to (Lau, Bioorg. Med. Chem. 1995) 
[35]. 148    The Open Biochemistry Journal, 2008, Volume 2  Poyarkov et al. 
conformation, it seems logical to assume that the fatty tail of 
lauric acid appears engaged in cooperation with D-
phenylalanine through the hydrophobic effect and located in 
the «hydrophobic cage» of the secondary binding site of 
thrombin. The authors of the article (Lau Bioorg. Med. 
Chem. 1995) [35] make a schematic diagram of active site 
showing key binding features of thrombin. In comparison the 
binding of our compounds with the known anticoagulant 
agratroban, we used this scheme to illustrate the occupation 
of the Laur-D-Arg-D-Phe-OMe in the active site of thrombin 
as it is shown in Fig. (3).  
  Argatroban has hydrophobic moieties that bind in the 
hydrophobic “P-pocket” and the “D-pocket, and a guanidi-
nium moiety that binds in the specificity pocket and forms a 
salt bridge with the carboxyl group of Asp 189. “P-pocket” 
and “D-pocket as used by Banner and Hadvary (Banner J 
Biol Chem 1991) [36]. The Tyr60A-Pro60B-Pro60C-Trp-
60D loop creates with Trp215. Leu99, and Ile174 a double 
hydrophobis pocket which they have divided into the P-
pocket (Proximal to the active site serine) and a D-pocket 
(distal to the active site serine. Nevertheless, we consider 
that through the absent of X-ray data of the thrombin com-
plexes with inhibitors containing in its structure fatty acid 
moiety it will be correct to consider the interaction of our 
new inhibitor with a whole hydrophobic cage without its 
division on pockets, as it is shown in Fig. (4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Schematic representation of interaction of inhibitor Laur-
DArg-DPhe-OMe with a whole hydrophobic cage without its sub-
division on pockets. 
 
  This supposition is confirmed by the enough low inhibi-
tion constants of both LAE (=2,0 ) and Laur-D-Arg-D-
Phe-OMe (=1,7 ). 
  In the structure of the compound Chrom-D-Arg-D-Phe-
OMe the chromone nucleus is remote from -amino group of 
D-arginine by two methylene groups that it results in more 
conformation mobility of the peptide as a whole and makes 
possible an interaction of the chromone nucleus with hydro-
phobic site of the secondary binding site of thrombin credi-
ble. Since the secondary binding center of thrombin is in 
direct proximity to the primary binding site, the competitive 
character of inhibition of these compounds, by experimental 
data of kinetic curves, complies with the suppositions made. 
CONCLUSIONS  
  This study have demonstrated unexpectedly high inhibi-
tion activity of compounds containing the lauric acid residue 
despite the traditional stereotype of structures of synthetic 
thrombin inhibitors containing aromatic substituents only. 
The discovery of sufficient effect of fatty acid residue on the 
potency of thrombin inhibitors opens up new possibilities to 
design new anticoagulants with the fatty acids moiety in fu-
ture.  
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